1. Home
  2. SSB vs TGTX Comparison

SSB vs TGTX Comparison

Compare SSB & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SouthState Corporation

SSB

SouthState Corporation

HOLD

Current Price

$102.54

Market Cap

9.9B

Sector

Finance

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$54.66

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSB
TGTX
Founded
1933
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.9B
8.5B
IPO Year
2008
2008

Fundamental Metrics

Financial Performance
Metric
SSB
TGTX
Price
$102.54
$54.66
Analyst Decision
Buy
Buy
Analyst Count
14
8
Target Price
★ $118.64
$69.71
AVG Volume (30 Days)
610.1K
★ 1.5M
Earning Date
10-21-2026
11-02-2026
Dividend Yield
★ 2.61%
N/A
EPS Growth
12.91
★ 1746.67
EPS
★ 4.64
0.17
Revenue
N/A
★ $2,785,000.00
Revenue This Year
$1.82
$55.81
Revenue Next Year
$6.61
$37.36
P/E Ratio
★ $21.86
$313.44
Revenue Growth
★ N/A
N/A
52 Week Low
$84.48
$26.76
52 Week High
$112.20
$59.30

Technical Indicators

Market Signals
Indicator
SSB
TGTX
Relative Strength Index (RSI) 47.99 44.79
Support Level $100.33 $51.68
Resistance Level $102.17 $58.26
Average True Range (ATR) 1.80 1.89
MACD 0.30 -0.13
Stochastic Oscillator 63.98 34.73

Price Performance

Historical Comparison
SSB
TGTX

About SSB SouthState Corporation

SouthState Bank Corp is a United States-based bank holding company. It provides a wide range of services and products to its customers through a wholly-owned bank subsidiary. The Bank provides retail and commercial banking services, mortgage lending services, trust and investment services, and consumer finance loans through financial centers in Alabama, Florida, Georgia, North Carolina, South Carolina, and Virginia. These services include demand, time, and savings deposits, lending and credit card servicing, ATM processing, and wealth management and trust services.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: